Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.

[1]  Ziv Bar-Joseph,et al.  Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. , 2014, American journal of respiratory and critical care medicine.

[2]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[3]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[4]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[5]  W. Busse,et al.  Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. , 2014, The Journal of allergy and clinical immunology.

[6]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[7]  H. Ortega,et al.  Characterisation of an OCS-dependent severe asthma population treated with mepolizumab , 2014, Thorax.

[8]  E. Ntzani,et al.  Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. , 2014, The journal of allergy and clinical immunology. In practice.

[9]  D. Curran‐Everett,et al.  Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. , 2014, The Journal of allergy and clinical immunology.

[10]  S. Wenzel,et al.  Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. , 2014, The Journal of allergy and clinical immunology.

[11]  P. Woodruff,et al.  Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. , 2014, The Journal of allergy and clinical immunology.

[12]  J. Holloway.  22 – Genetics and Epigenetics of Allergic Diseases and Asthma , 2014 .

[13]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[14]  E. Blood,et al.  Food , drug , insect sting allergy , and anaphylaxis A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients , 2013 .

[15]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[16]  W. Busse,et al.  Middleton's Allergy: Principles and Practice , 2013 .

[17]  A. Zwinderman,et al.  Severe adult-onset asthma: A distinct phenotype. , 2013, The Journal of allergy and clinical immunology.

[18]  S. Mun,et al.  Anti‐immunoglobulin E in the treatment of refractory atopic dermatitis , 2013, Clinical and experimental dermatology.

[19]  K. Nadeau,et al.  Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial , 2013, International Archives of Allergy and Immunology.

[20]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[21]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[22]  R. Flavell,et al.  TH2, allergy and group 2 innate lymphoid cells , 2013, Nature Immunology.

[23]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[24]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[25]  S. Spector,et al.  Atopic dermatitis: a practice parameter update 2012. , 2013, The Journal of allergy and clinical immunology.

[26]  W. Jin,et al.  IL-17 cytokines in immunity and inflammation , 2013, Emerging Microbes & Infections.

[27]  E. R. Sutherland,et al.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.

[28]  J. Just,et al.  Exhaled nitric oxide measurement confirms 2 severe wheeze phenotypes in young children from the Trousseau Asthma Program. , 2012, The Journal of allergy and clinical immunology.

[29]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[30]  Deborah A Meyers,et al.  IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. , 2012, The Journal of allergy and clinical immunology.

[31]  J. Just,et al.  Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze. , 2012, The Journal of allergy and clinical immunology.

[32]  P. O'Byrne,et al.  Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[34]  I. Annesi-Maesano,et al.  Two novel, severe asthma phenotypes identified during childhood using a clustering approach , 2012, European Respiratory Journal.

[35]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[36]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[37]  C. Bachert,et al.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. , 2011, The Journal of allergy and clinical immunology.

[38]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[39]  R. Pratley,et al.  Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. , 2011, The Journal of allergy and clinical immunology.

[40]  S. Spector,et al.  A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. , 2011, The Journal of allergy and clinical immunology.

[41]  Carole Ober,et al.  The genetics of asthma and allergic disease: a 21st century perspective , 2011, Immunological reviews.

[42]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[43]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[44]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[45]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[46]  R. Wood,et al.  Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. , 2011, The Journal of allergy and clinical immunology.

[47]  Mario Castro,et al.  Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2011, The Journal of allergy and clinical immunology.

[48]  D. Jarvis,et al.  Identifying adult asthma phenotypes using a clustering approach , 2011, European Respiratory Journal.

[49]  Ramirez Me,et al.  Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. , 2011 .

[50]  A. Burks,et al.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. , 2011, The Journal of allergy and clinical immunology.

[51]  G. Stingl,et al.  Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[52]  IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. , 2010, The Journal of allergy and clinical immunology.

[53]  C. Mackay,et al.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. , 2010, The Journal of allergy and clinical immunology.

[54]  W. Busse,et al.  Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[55]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[56]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[57]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[58]  U. Wahn,et al.  Safety of anti‐IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[59]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[60]  B. Lanier,et al.  Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. , 2009, The Journal of allergy and clinical immunology.

[61]  C. Beglinger,et al.  Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial , 2009, Gut.

[62]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[63]  E. Kerwin,et al.  A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. , 2009, American journal of respiratory and critical care medicine.

[64]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[65]  K. Rabe,et al.  Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti‐IgE treatment , 2009, Allergy.

[66]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[67]  E. Rickel,et al.  Identification of Functional Roles for Both IL-17RB and IL-17RA in Mediating IL-25-Induced Activities , 2008, The Journal of Immunology.

[68]  B. O'connor,et al.  Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease1 , 2008, The Journal of Immunology.

[69]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[70]  S. Wenzel,et al.  IL‐13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[71]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[72]  S. Holgate,et al.  The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial , 2008, Thorax.

[73]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[74]  J. Ring,et al.  Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. , 2007, The Journal of allergy and clinical immunology.

[75]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[76]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[77]  D. Curran‐Everett,et al.  IL4Rα Mutations Are Associated with Asthma Exacerbations and Mast Cell/IgE Expression , 2007 .

[78]  S. Ziegler,et al.  Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells , 2007, The Journal of experimental medicine.

[79]  C. Bachert,et al.  Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. , 2006, The Journal of allergy and clinical immunology.

[80]  P. Barnes,et al.  The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma , 2006 .

[81]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[82]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[83]  Vicki Seyfert-Margolis,et al.  Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[84]  P. Howarth,et al.  Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. , 2005, Thorax.

[85]  J. Ring,et al.  Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis , 2005, Allergy.

[86]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[87]  T. Chatila.  Interleukin-4 receptor signaling pathways in asthma pathogenesis. , 2004, Trends in molecular medicine.

[88]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[89]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[90]  S. Wenzel,et al.  Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. , 2004, The Journal of allergy and clinical immunology.

[91]  A. Burks,et al.  Effect of anti-IgE therapy in patients with peanut allergy. , 2003, The New England journal of medicine.

[92]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[93]  K. Bergmann,et al.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. , 2002, The Journal of allergy and clinical immunology.

[94]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[95]  J. Shellito,et al.  Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.

[96]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[97]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[98]  H. Milgrom,et al.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.

[99]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[100]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[101]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[102]  Salvi Ss,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. , 1999 .

[103]  K. Chung,et al.  Neutrophilic inflammation in severe persistent asthma. , 1999, American journal of respiratory and critical care medicine.

[104]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[105]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.

[106]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[107]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[108]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[109]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[110]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[111]  R. Pauwels,et al.  Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. , 1995, American journal of respiratory cell and molecular biology.

[112]  R. Pauwels,et al.  Tumor necrosis factor causes bronchial hyperresponsiveness in rats. , 1992, The American review of respiratory disease.

[113]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[114]  C. Sanderson,et al.  Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. , 1989, Blood.

[115]  H. Brown.  Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. , 1958, Lancet.